Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & Administrative
Others
Ratios

Pasithea Therapeutics (KTTA) Research & Development (2022 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Research & Development for 3 consecutive years, with $1.5 million as the latest value for Q4 2024.

  • Quarterly Research & Development fell 54.95% to $1.5 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $7.2 million through Dec 2024, down 11.14% year-over-year, with the annual reading at $8.0 million for FY2025, 10.87% up from the prior year.
  • Research & Development hit $1.5 million in Q4 2024 for Pasithea Therapeutics, down from $1.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $3.4 million in Q4 2023 to a low of $1.1 million in Q1 2023.
  • Historically, Research & Development has averaged $1.9 million across 3 years, with a median of $1.6 million in 2023.
  • Biggest five-year swings in Research & Development: skyrocketed 141.73% in 2023 and later tumbled 54.95% in 2024.
  • Year by year, Research & Development stood at $1.4 million in 2022, then surged by 141.73% to $3.4 million in 2023, then crashed by 54.95% to $1.5 million in 2024.
  • Business Quant data shows Research & Development for KTTA at $1.5 million in Q4 2024, $1.6 million in Q3 2024, and $2.4 million in Q2 2024.